超低剂量地西他滨治疗骨髓增生异常综合征的效果  

Effect of ultra-low dose of dicitabine on myelodysplastic syndrome

作　　者：刘丽娜 刘玉章 王耀美 梁利杰 王娟 林全德 刘晴 宋永平 房佰俊 Liu Lina;Liu Yuzhang;Wang Yaomei;Liang Lijie;Wang Juan;Lin Quande;Liu Qing;Song Yongping;Fang Bajun(Department of Hematology,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,China)

机构地区：[1]郑州大学附属肿瘤医院血液科河南省肿瘤医院血液科,郑州450008

出　　处：《临床医学》2024年第12期96-98,共3页Clinical Medicine

基　　金：国家自然科学基金(81900108);中原英才计划资助项目(214200510023);河南省高等学校重点科研项目计划(22A320061)。

摘　　要：目的观察超低剂量地西他滨治疗骨髓增生异常综合征(MDS)患者的临床疗效及安全性。方法选择2015年1月至2019年1月在郑州大学附属肿瘤医院住院确诊并采用超低剂量地西他滨方案治疗的46例MDS患者为研究对象。所有患者均采用增加给药频率的方式给予超低剂量地西他滨治疗。观察临床疗效及不良反应。结果46例MDS中完全缓解(CR)9例,骨髓缓解伴血象不完全恢复(CRi)+血液学进步(HI)18例,HI 4例,疾病无进展(SD)10例,疾病进展(PD)5例,CR率为19.6%,HI为47.8%,总反应率(ORR,即CR、CRi+HI与HI之和)为67.4%。治疗期间患者均出现一过性骨髓抑制,其中2例患者诱导治疗过程中出现中度骨髓抑制,未见3~4级治疗相关不良反应。结论采用增加给药频率的方式给予超低剂量地西他滨治疗骨髓增生异常综合征安全有效。Objective To observe the clinical efficacy and safety of ultra-low dose of dexamethabine in the treatment of myelodysplastic syndrome(MDS).Methods A total of 46 patients with MDS who were admitted to the Affiliated Cancer Hospital of Zhengzhou University from January 2015 to January 2019 and treated with ultra-low dose decitabine regimen were selected as the study objects.All patients were treated with an ultra-low dose of decitabine and an increased frequency of administration.The clinical curative effect and adverse reactions were observed.Results Among the 46 MDS patients,9 cases had complete response(CR),18 cases had bone marrow response with incomplete hemologic recovery(CRi)+hematologic progress(HI),4 cases had HI,10 cases had no disease progression(SD),and 5 cases had disease progression(PD).The CR was 19.6%,the HI was 47.8%,and the total response rate(ORR,CR and CRi+HI and HI)was 67.4%.All patients had transient myelosuppression during treatment,of which 2 patients had moderate myelosuppression during induction therapy,and no grade 3 to 4 treatment-related adverse reactions were observed.Conclusions The treatment of myelodysplastic syndrome with ultra-low dose of decitabine is safe and effective by increasing the frequency of administration.

关 键 词：地西他滨 超低剂量 骨髓增生异常综合征 

分 类 号：R551.3[医药卫生—血液循环系统疾病]